Publications 2023

Compagnucci A , Chan MK, Saïdi Y, Cressey TR, Bamford A, Riault Y, Coelho A, Nolan A, Chalermpantmetagul S, Morkunaite G, Amuge P, Musiime V, Violari A, Cotton M, Kekitiinwa AR, Kaudha E, Groenewald M, Liberty AA, Kanjanavanit S, Volokha A, Bologna R, Pavia Ruz N, Prieto Tato L,
Paioni P, Marques L, Reliquet V, Niehues T, Welch SB, Ford D, Giaquinto C, Gibb DM,
Babiker A, Ramos Amador JT, SMILE-PENTA17-ANRS 152 Trial Group. Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial. eClinicalMedicine 2023 June Lien

Abdalla S, Compagnucci A, Zheng Y, Tréluyer JM, Saidi Y, José T Ramos, Coelho A, Riault Y, Cressey T,  Hirt D, SMILE Study group. Population pharmacokinetics of unbound and total dolutegravir concentrations in children aged 12 years and older: a PK substudy of the SMILE trial. J Antimicrob Chemother 2023 Mar 3 Lien PubMed

Chaix ML, Leturque N, Gabassi A, Charreau I, Minier M, Pialoux G, Cua E, Chidiac C, Raffi R, Tremblay C, Meyer L, Molina JM, Delaugerre C and the ANRS IPERGAY study group. P revalence and Incidence of HEV among Men using HIV pre-exposure prophylaxis: a sub-study of the ANRS IPERGAY trial. Journal of Clinical Virology. J Clin Virol.2023 Mar Lien PubMed